GSK Seeks Ax Of Zofran Birth Defect Claims

By Emily Field (June 11, 2019, 4:57 PM EDT) -- GlaxoSmithKline on Tuesday asked a Massachusetts federal judge to toss certain claims in multidistrict litigation alleging that its anti-nausea drug Zofran caused birth defects, saying that the patients hadn't shown the drug caused some of the purported defects.

GSK said that the patients hadn't shown scientific evidence that the medication caused birth defects other than heart defects and cleft palates, and that claims over other types of birth defects, like clubfeet or Down's Syndrome, should be axed. At an April hearing, counsel for the patients admitted that they don't have the needed scientific support to prove causation in cases that don't...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!